BRAF and malignant colon neoplasm: Since our data indicate the role of p-NPM1 (Thr199) in regulating the resistance of BRAF-mutated colon cancer cells to BRAF inhibition, we hypothesized that tumor tissues from BRAF-mutated colon cancer patients, who present with an aggressive clinical phenotype and have a generally poor response to systemic chemotherapy, could have an increased abundance of p-NPM1.